Taletrectinib and Lenacapavir Injection: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lenacapavir Injection
Taletrectinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased taletrectinib exposure and an increased risk of taletrectinib-related adverse reactions
Interaction Deep Dive
Avoid concomitant use of taletrectinib (CYP3A4 substrate) with moderate CYP3A4 inhibitors as it may increase taletrectinib exposure, which may increase taletrectinib-related adverse reactions. In a drug interaction study, concomitant use with moderate CYP3A4 inhibitors (fluconazole, erythromycin, or verapamil) is predicted to increase taletrectinib AUC up to 2.6-fold and Cmax up to 1.5-fold1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of taletrectinib
Literature reports
1 report — tap to read
a) In a drug interaction study, concomitant use with moderate CYP3A4 inhibitors (fluconazole, erythromycin, or verapamil) is predicted to increase taletrectinib AUC up to 2.6-fold and Cmax up to 1.5-fold 1.
Common questions
Can I take Taletrectinib and Lenacapavir Injection together?
Increased taletrectinib exposure and an increased risk of taletrectinib-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Taletrectinib and Lenacapavir Injection interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Taletrectinib or Lenacapavir Injection need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: IBTROZI(TM) oral capsules, taletrectinib oral capsules. Nuvation Bio Inc. (per Manufacturer), Burlington, MA, 2025. DailyMed
Keep reading about Lenacapavir Injection
Keep reading about Taletrectinib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist